[go: up one dir, main page]

WO2024245965A1 - Détection d'antigènes - Google Patents

Détection d'antigènes Download PDF

Info

Publication number
WO2024245965A1
WO2024245965A1 PCT/EP2024/064448 EP2024064448W WO2024245965A1 WO 2024245965 A1 WO2024245965 A1 WO 2024245965A1 EP 2024064448 W EP2024064448 W EP 2024064448W WO 2024245965 A1 WO2024245965 A1 WO 2024245965A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
target
sample
detection
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/064448
Other languages
English (en)
Inventor
Michael Stockton
Mark Hooper
Michael Hausmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AliveDx Suisse SA
QBD (QS-IP) Ltd
Original Assignee
AliveDx Suisse SA
QBD (QS-IP) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AliveDx Suisse SA, QBD (QS-IP) Ltd filed Critical AliveDx Suisse SA
Publication of WO2024245965A1 publication Critical patent/WO2024245965A1/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Definitions

  • the present disclosure provides an improved method of detecting the presence of Hepatitis B virus, or an antigen therefrom, in a sample.
  • Hepatitis B virus is one of the world's most widespread infectious agents that can cause lifelong, chronic infection, cirrhosis of the liver, liver cancer, liver failure, and death (Liang et al., Hepatology, 49(5): S13- 21 (2009)). Early screening and detection of HBV infection is critical in disease management and the control of the spread of HBV (Franco et al., World J. Heptaol., 4: 74-80 (2012)).
  • HBV antigen(s) typically involve serological detection of HBV antigen(s), such as ELISA-based techniques or other immunoassays that detect HBV surface antigen (HBsAg), hepatitis core antigen (HBcAg) and/or hepatitis B surface antibody (Mao et al., Anal. Chim. Acta, 909: 101-108 (2016)).
  • HBV surface antigen HBsAg
  • HBcAg hepatitis core antigen
  • hepatitis B surface antibody hepatitis B surface antibody
  • real-time PCR or various sequencing techniques may be adopted to detect the presence of HBV DNA, such as to aid in the management of patients with chronic HBV infection undergoing anti-viral therapy, to measure HBV DNA levels at baseline, or during treatment to aid assessment of response to treatment (Terrault et al., Hepatology, 63(1): 261-282 (2015)).
  • the present disclosure is based on the finding that immunoassays comprising target capture and target detection steps, which use recombinant antibodies in both said capture and detection steps, represent an improvement over prior art immunoassays which, at best, may only use recombinant antibodies in one of the capture or detection steps.
  • the terms “comprise”, “comprising” and/or “comprises” is/are used to denote that aspects and embodiments of this invention “comprise” a particular feature or features. It should be understood that this/these terms may also encompass aspects and/or embodiments which “consist essentially of” or “consist of’ the relevant feature or features.
  • the various aspects and embodiments of this disclosure are applicable to immunoassays for the detection of target antigens in a sample.
  • the term ‘target’ may include a ‘target antigen’ or ‘target antigens’.
  • one aspect of the disclosure provides an immunoassay, for the detection of a target in a sample, wherein said immunoassay comprises target capture and target detection steps and both the target capture and target detection steps comprise recombinantly generated antibodies (or ‘recombinant antibodies’).
  • a second aspect of the disclosure provides recombinant antibodies for use in the target capture and target detection steps of an immunoassay for the detection of a target in a sample.
  • immunoassay refers to an assay method which is used to determine whether or not a sample contains a particular target.
  • immunoassay refers to an assay method which is used to determine whether or not a sample contains a particular target.
  • the term ‘immunoassay’ may embrace an enzyme immunoassay (EIA: for example an ELISA), a radioimmunoassay (RIA), a fluoroimmunoassay (FIA); a Western blot (WB); a chemiluminescent immunoassay (CIA) and counting immunoassay (CIA); immunohistochemistry-type assays (IHC); immunocytochemistry-type assays (ICC).
  • EIA enzyme immunoassay
  • RIA radioimmunoassay
  • FFA fluoroimmunoassay
  • WB Western blot
  • CIA chemiluminescent immunoassay
  • CIA immunohistochemistry-type assays
  • IHC immunocytochemistry-type assays
  • ICC immunocytochemistry-type assays
  • the term immunoassay may not embrace a radioimmunoassay (RIA).
  • the target may be an antigen.
  • the target may comprise an antigen known to be expressed by a pathogen, for example a fungal, bacterial or viral antigen.
  • An immunoassay of this disclosure may comprise a target capture step in which a sample is contacted with a target capture agent under conditions which permit binding between any target present in the sample and the target capture agent.
  • the target capture agent may comprise a recombinant antibody.
  • the recombinant antibody for use as a target capture agent may bind to the target (e.g. the target antigen). Binding between any target present in the sample and the target capture agent will yield a target/target capture agent complex.
  • the target capture agent may be immobilised to a substrate.
  • An immunoassay of this disclosure may further comprise a detection step in which target/target capture agent complexes (formed during the capture step of the immune assay) are contacted with a detection agent.
  • the detection agent may comprise a recombinant antibody.
  • the recombinant antibody for use as a detection agent may bind to the target (e.g. target antigen).
  • the recombinant antibody for use as a detection agent may bind to the target at a site or epitope, which is different from that bound by the capture agent.
  • the detection agent may be conjugated to a detectable moiety, for example an optically detectable moiety.
  • a detection system for use in any of the methods or assays described herein may comprise, for example, biotin-based systems, HRP-based systems; streptavidinbased systems; silver and/or gold staining-based systems and/or alkaline phosphatase-based systems.
  • a section system for use in a method or assay of this disclosure may comprise a streptavidin Poly-HRP conjugate (a biotin-binding protein conjugated with polymers of horseradish peroxidase).
  • a third aspect of the disclosure provides a method of detecting a target, for example a target antigen in a sample, said method comprising: contacting a sample with a first recombinant antibody under conditions suitable to permit binding between the first recombinant antibody and any target in the sample; and then contacting any first recombinant antibody/target complexes (formed by binding events between the first antibody and any target present in the sample) with a second antibody under conditions suitable to permit binding between said second antibody and any first recombinant antibody/target complexes; and then detecting second antibody bound to first recombinant antibody/target complexes; wherein detection of second antibody bound to a first recombinant antibody/target complexes indicates that the sample contains the target.
  • a target for example a target antigen in a sample
  • the first recombinant antibody may be immobilised to a substrate.
  • the above method may comprise one or more washing step(s).
  • the assay may be subject to a wash designed to wash away any unbound first antibody.
  • the method may comprise a second wash after the step of contacting any first recombinant antibody/target complexes with a second recombinant antibody, the additional wash being designed to remove unbound second recombinant antibody.
  • recombinant antibody technology allows customisation of the desired specifications for both the capture and detection antibodies; in this way the very best target binders can be selected. This delivers an immunoassay with (relative to prior art assays which do not use recombinant antibodies in both capture and detection steps) improved sensitivity and specificity; and
  • recombinant antibodies can be easily manipulated and/or converted to adopt any desired predetermined format, fragment type or class;
  • antibodies generated using recombinant technology can be generated quickly and cost effectively.
  • the antigen may comprise a pathogen antigen (e.g. a bacterial, viral or fungal antigen) and the presence of that antigen in a sample may be associated with a specific disease, infection or condition caused or contributed to by the pathogen expressing that antigen. Therefore, the finding that a sample comprises a particular antigen may indicate that the sample has been provided by or obtained from, a subject infected with a pathogen expressing that antigen or suffering/convalescing from a disease or condition caused or contributed to by a pathogen expressing that antigen.
  • a pathogen antigen e.g. a bacterial, viral or fungal antigen
  • a recombinant antibody for use as a capture or detection agent may be generated using established recombinant methods.
  • recombinant methods for the generation of useful antibodies may include the use of molecular techniques to generate recombinant antibody libraries, antibody display technology, antibody selection protocols, affinity maturation techniques. Further detail on the recombinant techniques used to generate antibodies, may be found in Hoogenboom, (2005); Nature Biotechnology,
  • suitable antibody display technologies may include those referred to as phage (antibody) display, ribosome (antibody) display and/or microbial (antibody) cell display.
  • Techniques for recombinant antibody selection may include exposing the antibodies of the display library to antigen. Such techniques may include, for example biopanning to select for clones (e.g. phage clones) which exhibit the desired binding characteristics.
  • clones e.g. phage clones
  • Selection procedures may comprise repeated rounds of selection in order to derive antibodies exhibiting the very best binding properties.
  • selection techniques may be used to select antibodies for use in capture and detection steps of the immunoassays described herein.
  • Affinity maturation is a process by which properties such as antibody potency and antibody affinity may be improved, developed and/or manipulated.
  • the processes may comprise the generation of libraries with focused diversity at a small number of residues most likely to be involved in target/antigen interaction.
  • the CDRs are built using, for example, amplification techniques (e.g. PCR) and libraries screened to identify variants with the desired characteristics.
  • Other approaches include the use of ‘selection pressures’ in order to select antibodies which bind best (to their targets) under specific conditions. These approaches can result in antibodies exhibiting substantial gains in affinity/potency etc.
  • Antibodies for use in an immunoassay of this disclosure may comprise antibodies obtainable using recombinant techniques, including those described herein.
  • antibodies for use as capture and detection agents in an immunoassay of this invention may be obtained as antibody (capture and detection) pairs exhibiting, for example, specific and predetermined target binding and/or potency and/or affinity properties.
  • an immune assay of this disclosure (versus prior art methods which do not use capture and detection antibodies which are recombinant and generated using the techniques described herein) may exhibit an improved level of sensitivity.
  • the disclosure provides a method for the selection of capture and detection antibodies for use in an immunoassay for the detection of a target, said method comprising, preparing recombinant capture antibodies and recombinant detection antibodies and selecting a capture/detection recombinant antibody pair which, in the immunoassay, exhibit the desired level of target detection sensitivity and/or selectivity.
  • this disclosure may relate to immunoassays for the detection of hepatitis B antigens in samples. It should be noted that the various definitions provided with respect to an immunoassay for the detection of hepatitis antigens, might also apply to the general disclosure of immunoassays which use recombinant antibodies for both the capture and detection steps (for example, sample source and subject type).
  • an immunoassay for the detection of a hepatitis B antigen in a sample may comprise the use of antigen capture and detection steps both of which comprise recombinant antibodies - in other words a recombinant antibody for use as a capture agent (an agent for capturing and/or immobilising a target from a sample) and a recombinant antibody for use in the detection of said target.
  • an immunoassay for the detection of a hepatitis B antigen in a sample may comprise a capture step in which a recombinant antibody is used as the capture agent (to capture any hepatitis B antigen in the sample) and a detection step in which any captured target is labelled for detection using a recombinant antibody.
  • the recombinant antibody for use as the capture agent may be immobilised to a substrate.
  • the recombinant antibody for use as the detection agent may be conjugated to a detectable moiety.
  • the present disclosure is further based on the unexpected finding that a specific combination of capture and detection (recombinant) antibodies against a hepatitis B antigen exhibits exceptional sensitivity. Without wishing to be bound by theory, it is suggested that the improved methods described herein are the result of the combined high binding capacity of the antibodies.
  • a method of detecting a hepatitis B virus (HBV) antigen for example a HBV target antigen
  • a hepatitis B virus (HBV) antigen for example a HBV target antigen
  • said method comprising contacting the sample with first (capture) and second (detection) antibodies, wherein both the first and second antibodies bind the HBV antigen.
  • HBV hepatitis B virus
  • the first and second antibodies are recombinant antibodies or fragments thereof.
  • the step of contacting comprises contacting the first and second antibodies with the sample under conditions which permit binding between the first and second antibodies and any of the HBV target antigen present in the sample.
  • the contacting step(s) may yield an antigen-antibody complex, wherein the antigen-antibody complex comprises the first and second antibodies bound to the HBV antigen.
  • the method may further comprise a detecting step.
  • the detecting step may be used to detect the presence of antigen-antibody complexes as described herein.
  • the detection of an antigenantibody complex indicates that the sample comprises the HBV antigen.
  • one embodiment of the described method comprises contacting the sample with a first and a second antibody under conditions which permit binding between the first and second antibody and any HBV antigen present in the sample, and detecting the resulting antigen-antibody complexes, wherein detection of antigen antibody complexes indicates that the sample comprised the HBV antigen.
  • an antibody for example the first antibody, may be immobilised on or to a substrate.
  • the substrate may comprise glass, polystyrene or any other material suitable for the immobilisation of an antibody.
  • the substrate may be suitable for use in imaging, microscopic observation and/or optical procedures/measurements and/or in cell culture.
  • the substrate may comprise a coating, such as to promote the binding and/or immobilisation of the antibody (for example the first antibody) to the substrate and/or to inhibit the immobilisation or binding of other antibodies, proteins (peptides), molecules and/or reagents. These other antibodies, proteins (peptides), molecules and/or reagents may be present in the sample.
  • an antibody for example the first antibody
  • the substrate may be blocked, in order to mask further binding sites on the substrate. Blocking may also help reduce non-specific binding events which may contribute to false positive results.
  • a ‘blocking’ procedure may use, for example, gelatin, BSA, skimmed milk or some other blocking agent.
  • this disclosure provides a method of detecting a hepatitis B virus (HBV) antigen in a sample, said method comprising contacting the sample with first and second antibodies, wherein both the first and second antibodies bind the HBV antigen and the first antibody is immobilised to a substrate.
  • HBV hepatitis B virus
  • any antigen-antibody complexes formed as the method is used i.e. by binding events between the first and second antibodies and any target HBV antigen present in the sample
  • any antigen-antibody complexes formed as the method is used i.e. by binding events between the first and second antibodies and any target HBV antigen present in the sample
  • the step of detecting may comprise detecting antigen-antibody complexes, wherein successful detection of antigen-antibody complexes indicates that the sample contains the target HBV antigen (and may have been obtained from or provided by a subject suffering from an HBV infection).
  • the detecting step need not be limited to a particular method of detection and antigen-antibody complexes of the type described herein may be detected using any suitable technique known in the art.
  • the first and/or second antibody preferably the second antibody
  • the first and/or second antibody may comprise a detectable moiety.
  • the first and/or second antibody preferably the second antibody
  • the detectable moiety may produce, either directly or indirectly, a detectable signal, such as an optically detectable signal.
  • the detectable moiety may be suitable for fluorescence detection, absorbance detection, enzyme-mediated detection, chromogenic and/or chemiluminescent detection.
  • a detectable moiety may be radio-opaque or a radioisotope, such as 3H, 14C, 32P, 35S, 1231, 1251, 1311; biotin; a fluorescent (fluorophore) or chemiluminescent (chromophore) compound, such as fluorescein isothiocyanate, rhodamine or luciferin; an enzyme, such as alkaline phosphatase, p-galactosidase or horseradish peroxidase; an imaging agent; or a metal ion.
  • a radioisotope such as 3H, 14C, 32P, 35S, 1231, 1251, 1311
  • biotin such as 3H, 14C, 32P, 35S, 1231, 1251, 1311
  • a fluorescent (fluorophore) or chemiluminescent (chromophore) compound such as fluorescein isothiocyanate, rhodamine or luci
  • the antibodies used in the methods of this disclosure may be used in any order.
  • the antibodies may be added to the sample at the same time.
  • the sample may be contacted with one of the antibodies before it is contacted with the other antibody.
  • the second antibody may be provided together with the sample and/or the second antibody may be provided subsequent to contacting the first antibody with the sample.
  • a method of this disclosure may comprise multiple contacting steps, for example a contacting step in which the sample is contacted with the first (optionally immobilised) antibody and the sample/first antibody mix incubated under conditions which permit binding between the first antibody and any target HBV antigen. After a suitable period of incubation, the sample/first antibody mix may be subject to a wash step.
  • washing will not remove the immobilised first antibody; indeed washing at this point will remove the sample leaving the immobilised first antibody which (depending on the antigen content of the sample) is either bound or unbound to the target antigen. In other words, washing will leave a mix of immobilised first antibody and/or immobilised first antibody/target antigen complexes. The number of immobilised first antibody/target antigen complexes will depend on the target HBV antigen content of the sample.
  • the method may further comprise a subsequent contacting step in which the sample is contacted with the washed and immobilised first antibody and/or any immobilised first antibody/target antigen complexes.
  • This step may be conducted under conditions which permit binding between the second antibody and any target antigen present in an (immobilised) first antibody/target antigen complex.
  • the system (or assay) may be washed. Washing at this stage will remove unbound second antigen, leaving only the second antibody bound to target antigen bound to the first (and immobilised) antibody.
  • the method may then be subjected to the described detection step in order to detect the presence of first antibody/target antigen/second antibody complexes.
  • a method of this disclosure may comprise one or more wash steps.
  • the assay may be washed to remove antibody that has not bound to its target.
  • the one or more wash steps will reduce the occurrence of false positive results.
  • the present invention is based on the identification of a combination of anti-hepatitis B antigen antibodies which can be used to enhance the detection of HBV antigen in a sample.
  • the methods described herein can detect a hepatitis B antigen in a sample obtained from early infection patients at the required regulatory limit.
  • the improved methods and/or assays of this disclosure may be used to facilitate the diagnosis of hepatitis B in a subject - wherein the detection of a HBV target antigen in a sample using a method described herein) may indicate that the subject providing the sample or from whom the sample was obtained, may be suffering or convalescing from an HBV infection.
  • a sample to be subject to a method of this disclosure may be provided or obtained from any suitable subject, including, for example healthy subjects with no apparent signs or symptoms of a hepatitis B viral infection.
  • the sample may be provided or obtained from a subject who has, or is suspected of having, a hepatitis B virus infection.
  • sample may embrace any sample type thought capable of harbouring the HBV antigen.
  • the sample may comprise a bodily fluid, such as serum, blood (including whole blood or a fragment or fraction thereof, for example serum or plasma), saliva or urine from a subject, for example.
  • the sample may comprise a cell (or cells) or a tissue, for example a tissue biopsy.
  • the sample may comprise a liver biopsy.
  • subject may embrace any human or animal subject, including (as stated) healthy subjects or subjects thought to be predisposed, susceptible to an HBV infection, subjects known to have had or with an HBV infection and/or subjects convalescing from an HBV infection.
  • a sample (of whatever type) is contacted with a first and a second antibody.
  • the first and second antibodies provided herein specifically bind a HBV antigen.
  • the first and second antibody may bind the same antigen or different HBV antigens in a sample.
  • the first and the second antibody may bind the same epitope of a particular HBV antigen or different epitopes on the same HBV antigen.
  • an antigen refers to a substance that can elicit an immune response and promotes the generation of antibodies in a subject.
  • An “epitope”, also known as an “antigenic determinant”, as used herein refers to the portion of an antigen that elicits an immune response and is the portion of the antigen to which an antibody specifically binds.
  • an antigen, or any antigenic fragment thereof may comprise an epitope or epitopes recognised and specifically bound by the antibodies of this disclosure.
  • antibody refers not only to recombinant (first and second) antibodies, but to any (recombinant) immunoglobulin or intact molecule as well as to fragments thereof that bind to the target HBV antigen and/or a specific epitope thereof.
  • Such antibodies include, but are not limited to polyclonal, monoclonal, chimeric, humanised, single chain, Fab, Fab’, F(ab)’ fragments and/or F(v) portions of the whole antibody.
  • antibody fragment refers to an incomplete or isolated portion of the full sequence of the antibody which retains the antigen binding function of the parent antibody.
  • antibody fragments include Fab, Fab’, F(ab’)2, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. Fragments of antibodies disclosed herein are encompassed by the invention so long as they retain the desired affinity of the full-length antibody. In particular, an antibody fragment may be shorter by at least one amino acid compared to the full-length antibody.
  • telomere binding refers to the interaction between an antibody (for example the first and second antibodies described herein) and a target HBV antigen.
  • HBV antigen may embrace the hepatitis B surface antigen (HBsAg).
  • the first and second antibodies for use in a method or assay of this disclosure may bind (or have an affinity for) Hepatitis B surface antigen (HBsAg).
  • HBsAg Hepatitis B surface antigen
  • each of the first and second antibodies may bind an epitope present on HBsAg.
  • the first and second antibodies of the present disclosure are typically monoclonal antibodies.
  • an antibody for use in a method of this disclosure may specifically bind an antigen comprising, consisting essentially of or consisting of the following sequence (SEQ ID NO: 1), or a fragment or variant thereof (which fragment or variant also binds the antibody and/or comprises the relevant epitopes):
  • SEQ ID NO: 1 may comprise at least one, for example two epitope(s) recognised and/or bound by an antibody of this disclosure.
  • an antigen which is detectable using a method of this disclosure may comprise any one or more of the following:
  • the HBsAg antigen to be detected by a method of this disclosure may comprise a sequence which exhibits a level of sequence identity or homology with SEQ ID NO: 1.
  • an HBsAg antigen to be detected by a method of this disclosure may comprise a sequence having at least 60%, 65%, 70%, 75%, 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% identify/homology with the sequence of SEQ ID NO: 1.
  • an HBsAg antigen to be detected by a method of this disclosure may comprise a sequence comprising any suitable portion or fragment of the full 226 amino acids of SEQ ID NO: 1 .
  • a detectable portion or fragment of SEQ ID NO: 1 should always bind or be bound by the antibodies described herein and may comprise ‘n’ amino acids from the full SEQ ID NO: 1 sequence.
  • the term ‘n’ may represent any number of amino acids from about 5 (consecutive) amino acids of SEQ ID NO: 1 to about 225 (consecutive) amino acids of SEQ ID NO: 1.
  • a detectable portion or fragment of SEQ ID NO: 1 may comprise 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 221 , 222, 223 or 224 (consecutive) amino acids from SEQ ID NO: 1.
  • a detectable portion or fragment may comprise a first antibody-binding epitope and/or a second-antibody binding epitope.
  • a "variant" as used herein refers to a detectable antigen/amino acid sequence that is altered by one or more amino acids.
  • the variant may have "conservative” changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). Additionally or alternatively, a detectable variant may have "nonconservative” changes (e.g., replacement of glycine with tryptophan).
  • Analogous minor variations may also include amino acid deletions or insertions, or both. The skilled person would recognise various methods by which an amino acid sequence may be altered (e.g.
  • a detectable variant of an antigen for example an HBsAg antigen described herein may have 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% sequence identity to a reference protein or peptide sequence (e.g. SEQ ID NO: 1). In all cases a variant and detectable form of SEQ ID NO: 1 or any detectable fragment or portion therefore, should bind or be bound by any of the antibodies described herein..
  • the antibody for example the first antibody for use (as a capture agent) in a method of this disclosure may comprise the following heavy chain CDR sequences:
  • CDRH2 VIWAGGITNYNSALMS (SEQ ID NO: 3)
  • An antibody for example the first antibody for use in a method of this disclosure may comprise or further comprise the following light chain CDR sequences:
  • CDRL1 RASESVEYYGTSLMQ (SEQ ID NO: 5)
  • CDRL2 AASNVEP (SEQ ID NO: 6)
  • CDRL3 QQSRNVPWT (SEQ ID NO: 7)
  • a first antibody for use (as a capture agent) in a method of this disclosure may comprise the following heavy chain (HC) sequence:
  • Exemplary heavy and light chain sequences of a first (or capture) antibody for use in a method of this disclosure may comprise the sequences deposited in GenBank under accession numbers AF110502 (heavy chain sequence) and AF110503 (light chain sequence). Further exemplary heavy and light chain sequences of a first (or capture) antibody for use in a method of this disclosure are published in “Intracellular Expression of a Cloned Antibody Fragment Interferes with Hepatitis B Virus Surface Antigen Secretion”: Jasper zu Putlitz, Arne Skerra, Jack R. Wands: Volume 255, Issue 3, 24 February 1999, Pages 785-791” - the contents of which are incorporated herein by reference.
  • a first (or capture) antibody for use in a method of this disclosure may comprise CDR, light and/or heavy chain sequences which show a degree of identity to the relevant sequence of any of SEQ ID NOS: 2-9.
  • the term ‘degree of identity’ may embrace sequences which are at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the relevant sequence.
  • the antibody for example the first antibody for use (as a capture agent) in a method of this disclosure may comprise the Anti-HBsAg monoclonal antibody known as “5C3” (catalogue no. Ab00769-2.0; Absolute antibody).
  • a method of this disclosure may exploit the full or complete form of 5C3, the method may also use or exploit an antigen (i.e. HBsAg) binding fragment thereof.
  • an antigen i.e. HBsAg
  • the antibody for example the second antibody, for use in (a detection step of) a method of this disclosure may comprise the following heavy chain CDR sequences:
  • CDRH2 I I SYDGRITYYRDSVKG (SEQ ID NO: 11)
  • An antibody for example the second antibody for use in a method of this disclosure may comprise or further comprise the following light chain CDR sequences:
  • CDRL1 RSSQSLLHRSGNNYLD (SEQ ID NO: 13)
  • CDRL2 VGSNRAS (SEQ ID NO: 14)
  • CDRL3 MQALQTPRT (SEQ ID NO: 15)
  • a second antibody for use (as a detection agent) in a method of this disclosure may comprise the following heavy chain (HC) sequence:
  • a second (or detection) antibody for use in a method of this disclosure may comprise CDR, light and/or heavy chain sequences which show a degree of identity to the relevant sequence of any of SEQ ID NOS: 10-17.
  • the term ‘degree of identity’ may embrace sequences which are at least 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the relevant sequence.
  • the second (or detection) antibody, for use in a method of this disclosure may comprise the Anti-HBsAg monoclonal antibody known as Libivirumab (catalogue no. PX-TA1189; ProteoGenix).
  • Libivirumab catalog no. PX-TA1189; ProteoGenix
  • first and second antibodies may be interchanged - with the antibody referred to as the first antibody (e.g. 5C3) being used after the antibody referred to herein as the second antibody (e.g. Libivirumab).
  • the antibodies disclosed herein typically exhibit high affinity for a target epitope. More specifically, the antibodies disclosed herein typically exhibit high affinity for an epitope of an HBV antigen, for example, HBsAg. For example, the antibodies may exhibit a KD value in the range of 10' 9 to 10’ 13 .
  • a method of detecting HBsAg in a sample comprising contacting the sample with 5C3 and Libivirumab, wherein both 5C3 and Libivirumab bind HBsAg.
  • the step of contacting may comprise firsts contacting the sample with 5C3 under conditions which permit binding between any HBsAg present in the sample and the 5C3 antibody to yield 5C3/HBsAg complexes.
  • the step of contacting may further comprise contacting any 5C3/HBsAg complexes with Libivirumab under conditions which permit binding between the HBsAg component of any 53C/HBsAg complexes and Libivirumab to form 5C3/HBsAg/ Libivirumab complexes.
  • the method may further comprise a step of detecting 5C3/HBsAg/ Libivirumab complexes, wherein the detection of a 5C3/HBsAg/ Libivirumab complex, indicates that the sample has been obtained from or provided by a subject suffering or convalescing from a HBV infection.
  • the method of the present disclosure may optionally further comprise one or more wash steps.
  • the wash step may take place after contacting the first antibody but prior to contacting the second antibody with the sample.
  • a wash step may take place after contacting the second antibody with the sample.
  • a method of this invention may comprise washing steps designed to, for example, remove unbound 53C and/or Libivirumab antibody. This helps reduce the occurrence of false positive results.
  • the method may optionally further comprise one or more control assays.
  • a negative control assay may comprise contacting the first and second antibodies with a sample which is known not to contain the relevant target antigen. In such a scenario, no antigen antibody complexes will form and the detection (subject to appropriate wash steps) step will yield a negative result.
  • a positive control may comprise the use of a sample known to contain or which has been spiked with the relevant target antigen. In this scenario, antigen antibody complexes will form and the detection step should yield a positive result.
  • the method may further comprise one or more additional antibodies to further enhance the sensitivity and/or specificity of the assay.
  • the one or more additional antibodies may specifically bind another, different hepatitis B antigen, for example, the hepatitis B core antigen (HBcAg) and/or the hepatitis B e antigen (HBeAg).
  • the method need not be limited to the examples provided herein and may be carried out in any suitable format, including in single receptacles, such as Eppendorf or other tubes, or in a multiple format such as multi-well plates, for example. Additionally, cartridge formats, such as lateral flow or microfluidic based cartridges may be envisaged. It will be appreciated by the skilled reader that depending on the method of detection used and/or sample provided (e.g. bodily fluid or tissue), the format of the method may need to be adapted using various methods known in the art.
  • kits for use in the methods as described herein may comprise, consist essentially of, or consist of: a first antibody and a second antibody, wherein the first and/or second antibody are selected from:
  • Anti-HBsAg [5C3] (catalogue no. Ab00769-2.0; Absolute antibody), and optionally, the first antibody or the second antibody immobilised on a substrate, and further optionally, the first antibody and/or the second antibody labelled with a detection moiety.
  • the disclosure further provides use of Libivirumab (catalogue no. PX-TA1189; ProteoGenix) and/or 5C3 (catalogue no. Ab00769-2.0; Absolute antibody), in a method or assay for the detection of HBsAg in a sample.
  • FIG. 1 Immunoassay (ELISA) for the detection of HBsAg comparing various combinations of capture and detection antibodies.
  • FIG. 1 Immunoassay (ELISA) for the detection of HBsAg comparing various combination of capture and detection antibodies.
  • FIG. 3 Immunoassay (MosaiQ) for the detection of HBsAg comparing various combination of capture and detection antibodies.
  • FIG. 4 Immunoassay (MosaiQ) for the detection of HBsAg comparing various combination of capture and detection antibodies.
  • Figure 5 Analysis demonstrating sensitivity of assays using difdernt combiantions of capture and detection agent.
  • A capture: Absolute 5C3; Detection: proteogenix Libivirumab; Conjugate SDT Streptavidin poly-HRP 80; cycle time: 48s.
  • B capture: Absolute 5C3; Detection: Meridian B65811 ; Conjugate SDT Streptavidin poly-HRP 80; cycle time: 48s.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des dosages immunologiques d'une sensibilité exceptionnelle pour la détection d'antigènes cibles dans des échantillons. Dans un apprentissage, les étapes de capture et de détection relatives à ces dosages font appel à des anticorps recombinants. Les dosages immunologiques décrits peuvent trouver une application particulière dans la détection d'antigènes du VHB.
PCT/EP2024/064448 2023-05-26 2024-05-24 Détection d'antigènes Pending WO2024245965A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2307938.7A GB202307938D0 (en) 2023-05-26 2023-05-26 Antigen detection
GB2307938.7 2023-05-26

Publications (1)

Publication Number Publication Date
WO2024245965A1 true WO2024245965A1 (fr) 2024-12-05

Family

ID=87060949

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/064448 Pending WO2024245965A1 (fr) 2023-05-26 2024-05-24 Détection d'antigènes

Country Status (2)

Country Link
GB (1) GB202307938D0 (fr)
WO (1) WO2024245965A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008798A1 (en) * 2004-06-07 2006-01-12 Chien David Y Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same
CN101762701A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种检测乙肝表面抗原的磁性免疫层析试纸条及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060008798A1 (en) * 2004-06-07 2006-01-12 Chien David Y Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same
CN101762701A (zh) * 2009-06-24 2010-06-30 北京科美东雅生物技术有限公司 一种检测乙肝表面抗原的磁性免疫层析试纸条及其制备方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. AF110502
FRANCO ET AL., WORLD J. HEPTAOL., vol. 4, 2012, pages 74 - 80
HOOGENBOOM, NATURE BIOTECHNOLOGY, 2005
JASPER ZU PUTLITZARNE SKERRAJACK R. WANDS, INTRACELLULAR EXPRESSION OF A CLONED ANTIBODY FRAGMENT INTERFERES WITH HEPATITIS B VIRUS SURFACE ANTIGEN SECRETION, vol. 255, 24 February 1999 (1999-02-24), pages 785 - 791
LIANG ET AL., HEPATOLOGY, vol. 49, no. 5, 2009, pages 13 - 21
LIU Y S ET AL: "A monoclonal-antibody enzyme immunoassay for detection of hepatitis B surface antigen with use of a biotin-avidin system.", CLINICAL CHEMISTRY, vol. 31, no. 2, 1 February 1985 (1985-02-01), US, pages 202 - 205, XP093192735, ISSN: 0009-9147, Retrieved from the Internet <URL:http://academic.oup.com/clinchem/article-pdf/31/2/202/32768877/clinchem0202.pdf> DOI: 10.1093/clinchem/31.2.202 *
MAO ET AL., ANAL. CHIM. ACTA, vol. 909, 2016, pages 101 - 108
TAKAHASHI H ET AL: "Development of a second generation monoclonal immunoradiometric assay increased sensitivity leads to enhanced detection of hepatitis B viral infection", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 112, no. 2, 13 September 1988 (1988-09-13), pages 191 - 200, XP023656244, ISSN: 0022-1759, [retrieved on 19880913], DOI: 10.1016/0022-1759(88)90357-2 *
TERRAULT ET AL., HEPATOLOGY, vol. 63, no. 1, 2015, pages 261 - 282

Also Published As

Publication number Publication date
GB202307938D0 (en) 2023-07-12

Similar Documents

Publication Publication Date Title
JP4931963B2 (ja) 抗ｈｃｖコア蛋白質モノクローナル抗体
EP0158973B1 (fr) Essai immunométrique multisite
US12399176B2 (en) Methods for reducing interferences
WO2022265066A1 (fr) Procédé de dosage immunologique du sars-cov-2 et kit de dosage immunologique
CN117720650B (zh) 抗人呼吸道合胞病毒抗体及其应用
JP7198222B2 (ja) Ｂ型肝炎ウイルスｓ抗原の測定方法及び測定キット
CN104126124A (zh) 用于慢性hbv患者的反应预测和疗法监测的hbv免疫复合物
US6489131B1 (en) Interference reduction by rheumatoid factors
KR102390761B1 (ko) HBsAg의 정량적 검출을 위한 키트 및 방법
CN117683121A (zh) 抗水痘-带状疱疹病毒抗体及其应用
EP1752768A1 (fr) Procede de detection du virus de l&#39;hepatite b
JP4346798B2 (ja) Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
JP7141405B2 (ja) 検体検出イムノアッセイ
EP4189396A1 (fr) Épitope amélioré pour la détection et/ou la quantification d&#39;auto-anticorps contre l&#39;alpha-f?toprotéine
WO2019075109A1 (fr) Biomarqueurs dans une maladie hépatique auto-immune
WO2024245965A1 (fr) Détection d&#39;antigènes
JP2020506395A5 (fr)
CN118043666A (zh) 对定量药物和靶标浓度的测定
CN113196057B (zh) 病毒性肝癌的检测方法
TW202342979A (zh) 檢測方法及檢測試劑
CN101606066A (zh) 乙型肝炎病毒表面抗原的分析方法
US12442821B2 (en) Kit of in vitro quantifying large surface protein of hepatitis B virus (HBV), biomarker set for analyzing phases of HBV infection and hepatoma prognosis, and set of monoclonal antibodies for predicting, diagnosing or treating chronic liver disease
WO2025096611A1 (fr) Compositions de réactifs pour dosages immunologiques et leur utilisation dans la détection d&#39;antigène cancéreux 19-9
JP2003083976A (ja) ＨＢｓ抗原測定試薬
JP2001116751A (ja) 新規な免疫複合体転移測定法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24730207

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2024283078

Country of ref document: AU